Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
24/11/2021 09:02
Nov 24 (Reuters) - Cadila Healthcare Ltd CADI.NS :
* CADILA HEALTHCARE LTD., ENTERS INTO AN AGREEMENT WITH
ENZYCHEM
LIFESCIENCES OF REPUBLIC OF KOREA
* DEAL FOR MANUFACTURING LICENSE AND TECHNOLOGY TRANSFER FOR
PLASMID DNA VACCINE
* THIS PARTNERSHIP WILL LEAD TO AN ESTIMATED MANUFACTURING
OF 80
MILLION OR MORE DOSES OF PLASMID DNA VACCINE IN 2022
* WILL PROVIDE MANUFACTURING LICENSE AND TRANSFER PLASMID
DNA
VACCINE TECHNOLOGY TO ENZYCHEM LIFESCIENCES
* ENZYCHEM TO MANUFACTURE, COMMERCIALISE VACCINE WITHIN ITS
TERRITORY UNDER ZYDUS TRADEMARK
* CHL WILL RECEIVE LICENSE FEES AND ROYALTY PAYMENTS FOR
SAME
Source text for Eikon: ID:nBSE6g3cyf
Further company coverage: CADI.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot